Skip to navigation Skip to content



Apitope Announces Successful Completion of Second Phase I Trial of ATX-MS-1467, an Immune Therapy Whose Early Development was Supported by the National MS Society

September 10, 2013

Apitope Technology Ltd. announced that in a phase I study in 42 people with relapsing MS, the experimental treatment ATX-MS-1467 reduced disease activity on MRI scans when given intradermally (within the skin).  (Apitope press release, September 3, 2013). Details about its safety and tolerability were not announced.

Apitope was the first in a series of partnerships between the National MS Society’s drug development arm, Fast Forward, and early stage biotechnology companies. The company successfully leveraged this support by entering into a research, development and license agreement with Merck Serono for development and commercialization ATX-MS-1467.

Background: Multiple sclerosis involves immune attacks launched on the brain and spinal cord. Apitope has developed a proprietary approach to identify pieces of proteins, called “peptides” derived from human antigenic proteins that might be able to reinstate “immune tolerance”  – in effect, train immune cells to ignore target tissues – to suppress such an attack. ATX-MS-1467 is a mixture of four such peptides. An earlier clinical trial in 6 people with secondary-progressive MS indicated that the drug was well tolerated with early evidence of potential efficacy.

The Study: The current study recruited 42 people with relapsing MS (relapsing-remitting, and secondary-progressive with relapses). Participants were randomly assigned to receive ATX-MS-1467 delivered via injection into layers of skin (intradermally) or subcutaneously (under the skin), every two weeks, for a total of nine doses. Participants were then followed for 22 weeks.  (For further details, see the study’s listing on

The press release reports a significant decrease in disease activity seen on MRI scans in the group treated by intradermal injection, but not in those treated with subcutaneous (under the skin) injection.

Comment: The complete results of this study and further, phase II and phase III studies will help to determine whether ATX-MS-1467 has potential to be developed into a safe and effective treatment for people with MS. These results are an example of how, by connecting people, ideas, and resources, the Society is helping promising treatments to break through barriers, move through the pipeline, and enter clinical trials -- faster.

Read more about Society-supported research.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.